Dr. Michael Boehnke (University of Michigan) – who pioneered large-scale studies identifying genetic risk in diabetes and bipolar disorder – shared with us some recent insights about recent advances in exome and genome sequencing and their applications to better understand disease biology and etiology of psychiatric disorders, the relevance of statistical data analysis to overcome the burden of multiple testing, and how the genome can influence the epigenome to modulate gene expression and risk of type 2 diabetes.

Dr. Boehnke is a true pioneer in precision medicine having conducted a number of the first large scale studies to identify genetic risk in diabetes and bipolar disorder. As a biostatistician, Dr. Boehnke’s research focuses on the genetic dissection of complex traits. In his 35-year career he has developed methods for analysis of human pedigrees, examined the history of breast cancer in genetically at risk individuals, and contributed important discoveries on the genetics of type 2 diabetes and related traits, such as obesity and blood lipid levels. He has served on the University of Michigan faculty since 1984, focusing on problems of study design and statistical analysis of human genetic data with a particular emphasis on development and application of statistical methods for human gene mapping. His current focus is on disease and trait association studies based on genome sequence and genotype-array data. Read his full bio.

PMWC 2018 Michigan takes place June 6-7, 2018.

Q&A with Michael Boehnke

Q: Little is known about the molecular basis of mood and psychotic disorders such as bipolar and schizophrenia. How do genetic studies using whole genome or exome analysis provide us an insight for the development of novel drugs, therapies, and preventive strategies?

A: Genome-wide association studies (GWAS) based on genotype arrays or sequencing identify genetic variants associated with any disease (or trait), including these psychiatric disorders. Availability of low-cost arrays assaying millions of sites in the genome together with clever statistical and computational tools now allow us to assay all but the rarest or most complex genetic variation in hundreds of thousands or even millions of individuals. Exome and genome sequencing allow near-complete assay even of very rare genetic variation, but sequencing costs need to fall even further to allow the sample sizes we need to identify disease-associated variants with high statistical confidence. Each disease-associated region we identify provides a potential entry point to understand disease biology and etiology, to suggest targets for new drugs, or to better target existing drugs to people for whom they will be helpful and not harmful. Taking the step from associated variant to causal mechanism to a drug is challenging, and a major focus for both academic and pharmaceutical researchers. The good news is that drug targets suggested by genetic studies have a substantially higher rate of progressing through the drug development pipeline than those without support from genetic studies.

Q: What are the challenges and some of the solutions you developed for analyzing genome or exome sequence data from 10,000s of individuals?

A: Analysis of sequence data challenges us computationally and statistically. A BAM file which includes the complete information for a single human genome requires 25 x 109 bytes (25 gigabytes) of computer storage, so that for our NHLBI-funded TOPMed project which has to date sequenced >120,000 genomes requires storage of 3 x 1015 bytes (3 petabytes) of data. It was only a few years ago I learned what the prefix peta meant! Dealing with that much data requires careful consideration of issues such as minimizing data transfers and avoiding multiple data copies. While the cost of sequence data generation has dropped by many orders of magnitude, the cost of computer storage has dropped more slowly, making careful data management critical.

Statistical analysis of such large data files also is challenging and has required us to develop analysis software that is computationally very efficient. To test for association with many millions of sites in the genome requires extreme levels of statistical significance to overcome the burden of multiple testing, so that many of our standard statistical tests are no longer well behaved and have to be modified. For example, we use modified disease association tests when the number of cases with disease is much smaller than the number of controls without disease. Carrying out so many tests on such large samples also requires very careful quality control to avoid even a low rate of false positives that would swamp true association signals with spurious ones. For example, we developed methods to identify and discard DNA samples that are contaminated by DNA from another person.

Q: What are the challenges we face and the opportunities that exist in resolving the complex processes underlying common diseases such as breast cancer and obesity?

A: We geneticists always need to keep in mind that genetics is just small part of the overall picture, and that environmental and behavioral factors also are critical to health and disease. Still, genetic information has the advantages that it is simple (a 4-letter alphabet), finite (3 billion base pairs is a lot, but is finite), and does not change (so we can measure it once and use it forever), whereas behaviors and the environment change all the time and measuring and summarizing them is truly challenging. GWAS identify genetic regions associated with disease, providing valuable entry points to understand human biology and disease. We seek to move from genomic regions to specific causal variants, genes, and pathways, which in turn can illuminate the complex causal processes underlying these and other diseases.

Q: You published last year a paper on genetic regulatory signatures that are associated with increased risk for type 2 diabetics. What is the significance of this discovery and could it help lead to more personalized treatments for diabetes?

A: My research group and our collaborators are working to understand the genetic basis of type 2 diabetes. Our work has identified hundreds of regions in the human genome that impact risk to type 2 diabetes and variability to diabetes-related traits like glucose and insulin levels. An important next step is to identify the specific genes and genetic variants involved, and their mechanisms of action. In Varshney et al., we presented an integrated analysis of human pancreatic islet molecular profiling data. We found that genetic variants associated with type 2 diabetes are more frequently present in regions of the genome where transcription Regulatory Factor X (RFX) is predicted to bind in an islet-specific manner, and that genetic variants that increase type 2 diabetes risk are predicted to disrupt RFX binding. Our findings provide a molecular mechanism by which the genome can influence the epigenome, and so modulate gene expression and risk of type 2 diabetes. It is our hope that these sorts of mechanistic insights, that result from combining molecular data on open chromatin and gene expression with other sources of genomic annotation can help pinpoint the functional mechanisms underlying type 2 diabetes and lead to better understanding of type 2 diabetes etiology and treatment.

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More

Q&A with Mickey Kertesz, Chief Executive Officer, Karius

Q: Tell us a little bit about Karius – what problem(s)/need(s) are you trying to address and what technology is behind it to achieve this?

Read More

Join PMWC 2018 Michigan This June to Learn More about How the Modulation of the Epigenome Increases the Risk for Type 2 Diabetes

Dr. Michael Boehnke (University of Michigan) – who pioneered large-scale studies identifying genetic risk in diabetes and bipolar disorder – shared with us some recent insights about recent advances in exome and genome sequencing and their applications to better understand disease biology and etiology of psychiatric disorders

Read More

AI and Machine Learning in Healthcare – Not Just Hype Anymore

AI and machine learning has gotten a lot of attention over the last year, as it appears to be poised to become one of the biggest game changer in many industries, including the healthcare sector.

Read More

Q&A with Eric Lefkofsky, CEO of Tempus and Co-founder of Groupon

“Treating a cancer patient without the benefit of modern software is the same as driving at night without headlights”

Read More

PMWC Michigan – Big Data in Action: Data-Driven Insights in the Clinic

We are excited to launch the first Precision Medicine World Conference (PMWC) at the University of Michigan June 6-7, 2018.

Read More

Q&A with Susan A. Murphy, Harvard University

Q: Your lab develops experimental trial designs and data analysis methods for increasing the usefulness of mobile health interventions. Can you please give examples how these trials are being used in the areas of substance abuse, physical activity, or helping people quit smoking?

Read More

Q&A with Dr. Dara Richardson-Heron, Chief Engagement Officer, All of Us

Q: Your reputation for passion about engaging and empowering people precedes you. Can you please describe your role at the All of Us Research Program?

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Changing Pharmacogenomics
    • Community Setting Challenges
    • Patient Issues and Challenges
    • Legal and Ethical Issues
    • Integrating genomic data into EMRs
    • Emerging Technologies
    • Personalized Health Care Delivery
    • Personalized Modeling of Precision Health
    • NIH’s All of Us Study
    • Big Data in Action
    • Opioid Precision Health
    • Neurosciences
    • Big Data in the Clinic
    • Wellness and Aging
    • Epigenetics and Aging
    • Precision Cancer Therapy
    • Data Sharing in Translational Medicine
    • Economic and Socio-political Issues

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Changing Pharmacogenomics
        • Community Setting Challenges
        • Patient Issues and Challenges
        • Legal and Ethical Issues
        • Integrating genomic data into EMRs
        • Emerging Technologies
        • Personalized Health Care Delivery
        • Personalized Modeling of Precision Health
        • NIH’s All of Us Study
        • Big Data in Action
        • Opioid Precision Health
        • Neurosciences
        • Big Data in the Clinic
        • Wellness and Aging
        • Epigenetics and Aging
        • Precision Cancer Therapy
        • Data Sharing in Translational Medicine
        • Economic and Socio-political Issues

 

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Event Highlights

When
June 6, 2018 8:00am to June 7, 2018 5:00pm
Where
Ross School of Business
701 Tappan Ave
Ann Arbor, MI 48109
Cost
$774 by May 2nd, 2018

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.